The lung cancer drug boosted pharma giant AstraZeneca

Imfinzi showed promise in treating highly aggressive small cell lung cancer. FTSE 100 group is one of the largest in the world's most successful pharmaceuticals. AstraZeneca is the only UK company to be on the verge of a double digit rise in the share market this year.

Astra makes £2bn bid for cancer specialist Fusion Pharmaceuticals. Astra has snapped up several small firms since December including rare disease firm Amolyt Pharma. The company has also snapped up rare disease-resistant Amolet Pharma and rare disease specialist Amolyte Pharma.

Britain's biggest drugmaker to buy Canadian cancer specialist Fusion for $2.4bn. British drugmaker's latest acquisition will help it to develop new radiotherapy treatments. It is hoped Fusion will help develop new treatments for cancer patients in Canada and Europe. AstraZeneca to buy Fusion to help develop radiotherapy new treatments.

British pharma giant aims to bolster its pipeline of cancer drugs amid diagnosis delays. AstraZeneca snaps up rival to develop pioneering new cancer treatment. British drug giant hopes to bolster pipeline of new cancer drugs as diagnosis delays persistently plague the industry. AstroZeneca: We need to find a way to improve our quality of life in the world of cancer.

Britain's largest drugmaker intends to spend $2billion upfront for Canadian firm Fusion. Up to $400million in potential contingent payments will be made to Canadian firm. AstraZeneca intends to buy Fusion for $21 per share, equivalent to $21 a share.